In-vivo and in-vitro biofilm disruption, improved wound re-epithelialization and health economics data presented at Symposium on Advanced Wound Care
TEMPE, Arizona, May 4, 2015 /PRNewswire/ -- Procellera® from Vomaris Innovations, Inc. (now available through Arthrex as JumpStartTM) - the only antimicrobial wound dressing powered by Advanced Microcurrent TechnologyTM, was featured in two scientific presentations and three abstracts at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Spring conference held April 29 - May 2 in San Antonio, Texas. This latest research from Ohio State University reveals first reported results demonstrating in-vivo anti-biofilm efficacy, improved wound healing outcomes and health economics benefits.
Significant new findings on the anti-biofilm efficacy of the Advanced Microcurrent Technology were presented by researchers from the Ohio State University.
Anti-biofilm research results, titled "A Wireless Electroceutical Wound Dressing Disrupts Mixed Species Bacterial Biofilm In A Porcine Pre- clinical Model" were presented at the SAWC Spring WHS Young Investigators Symposium. Researchers tested the anti-biofilm properties of Procellera electroceutical wound dressing in a mixed biofilm-infected porcine burn wound model. Results revealed that the electroceutical dressing effectively disrupted biofilm, markedly improved wound re-epithelialization and restored skin barrier function, when compared to control dressings on wounds infected with both Psuedomonas aeruginosa and Acinetobacter baumannii.
Additional research from the same laboratory led by Professor Chandan Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center titled "Silver-zinc Redox-coupled Electroceutical Wound Dressing Disrupts Bacterial Biofilm", was selected as an awardee for the "Excellence in Translational and Regenerative Science Award" by the Wound Healing Society, honoring scientific work that fosters the development of cell-based and other therapies in wound healing and regenerative medicine toward clinical applicability.
Data also presented at the conference, "An Overview of Antimicrobial Efficacy of an Electroceutical Wound Care Device" by Hosan Kim, Ph.D. and Mina Izadjoo, Ph.D., both of the Biosciences Division of Trideum Corporation, further added to the growing body of antimicrobial evidence of this electroceutical dressing, highlighting its anti-biofilm activity and efficacy against a broad spectrum of harmful pathogens, including multi-drug resistant bacteria, to help reduce risk of infection.
The OSU researchers also presented findings from a new randomized clinical trial investigating use of the electroceutical dressing in conjunction with negative pressure wound therapy (NPWT) compared to a NPWT-alone control group in the treatment of patients undergoing abdominal wall surgery. In this abstract, "Wireless Electroceutical Dressing Lowers Cost of Negative Pressure Wound Therapy", researchers reported that the electroceutical dressing, when used as an adjunct to NPWT, decreased dressing changes and significantly reduced overall per-patient treatment cost by 20%1 as compared to the control group. Researchers further determined that use of the electroceutical dressing with NPWT tended to decrease the consumption of opioid analgesic pain medication, warranting further study. Further, these findings were published online this week in the May 2015 issue of the peer-reviewed journal Advances in Wound Care.
"These latest research findings, which include controlled and randomized clinical data, add strength to our robust and growing body of evidence," said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. "Research on our Advanced Microcurrent Technology continues to consistently substantiate antimicrobial and anti-biofilm efficacy, and now we can add cost efficiency when used as an adjunct to NPWT. We are pleased to provide evidence-based wound care solutions to physicians and patients, while offering significant value for facilities and payors."
About Vomaris Innovations
Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond. Utilizing electricity to mimic the body's own physiologic electric currents, which are essential for skin repair and wound healing, Vomaris' core technology platform employs imbedded microcell batteries that generate microcurrents in the presence of a conductive medium to harness the power of electricity to support healing.
Vomaris' flagship product, Procellera® Antimicrobial Wound Dressing is the only wound dressing in the world powered by Advanced Microcurrent Technology. It is a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial efficacy and the ability to promote wound healing, and is available exclusively through Arthrex as JumpStart Technology with Advanced Microcurrent Healing.
Procellera / JumpStart is currently used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. The company's ongoing mission is to develop and deliver evidence-based, patient-focused and cost-effective solutions, backed by a commitment to quality and innovation for the improvement of lives.
Arthrex, Inc. is a global medical device company and leader in new product development and medical education in orthopaedics. With a corporate mission of helping surgeons treat their patients better, Arthrex has pioneered the field of arthroscopy and developed more than 8,500 innovative products and surgical procedures to advance minimally invasive orthopaedics worldwide. Arthrex remains dedicated to delivering uncompromising quality to the healthcare professionals who use its products, and ultimately, the millions of patients whose lives these products impact.
- Ghatak PD, Schlanger R, Ganesh K, Lambert L, Gordillo G, Martinsek P, Sashwati R. A Wireless Electroceutical Dressing Lowers Cost of Negative Pressure Wound Therapy. Advances in Wound Care. Ahead of print. doi:10.1089/wound.2014.0615.